Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...

Eli Lilly (LLY) has signed a $1.3 billion deal with privately held biotechnology firm Superluminal Medicines that will see ...

The deal allows Eli Lilly and Company (NYSE:LLY) to have exclusive rights to develop and commercialize drug candidates ...

Superluminal Medicines, a healthcare company integrating AI/ML, announced partnership with Eli Lilly (NYSE:LLY) to advance ...

Superluminal will use its AI-driven platform to discover and optimize small-molecule treatments for G protein-coupled receptors, or GPCRs, which have emerged as a key to conditions such as diabetes ...

The Boston-based AI/ML startup focuses on endocrine and cardiometabolic diseases and will use that expertise to generate new ...

Yahoo Finance anchor Julie Hyman tracks Thursday's top stocks and market movers in this Market Minute. C3.ai (AI) stock dips ...

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.1% in the afternoon session after the stock rebounded ...

Hundreds of people may have been exposed to rabies in Wyoming, Eli Lilly has a new GLP-1 pill to help people lose weight and ...

Eli Lilly and Co. and Purdue Strategic Ventures recently participated in a $12 million funding round to support a new remote lab platform aimed at significantly decreasing the time it takes to ...

Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's AI-driven ...